RUDACURE

New Drug Candidate for Dry Eye syndrome

RCI 001

RCI001

Candidate substance for dry eye treatment with strong anti-inflammatory action

▪ Patents for domestic use 10-1816277, U.S. patent application
10-675294

▪ Domestic technology transfer: Hanlim Pharmaceutical Co., Ltd.

▪ Overseas L/O goal after Phase 2 clinical trials

▪ South Korea MFDS Phase 1 clinical trials: 2023 1H

▪ US FDA Phase 2 clinical trials: 2023 2H

{"google":["Noto Sans","Poppins"],"custom":["Nanum Square","Nanum Barun Gothic","Noto Sans KR"]}

{"google":["Noto Sans","Poppins","Roboto","Oswald"],"custom":["Nanum Square","Nanum Barun Gothic","Noto Sans KR"]}

Company Name RudaCure Co., Ltd ｜ CEO Yong Ho Kim ｜ CPO Seunghoon Kim
Location
HQ&Research Institute R302, BRC1, 9, Songdomirae-ro, Yeonsu-gu, Incheon, Republic of Korea
Seoul Office R1001, 145, Gasan digital 1-ro, Geumcheon-gu, Seoul, Republic of Korea
US Office 40W, 37th St. Suite 801 New York, NY 10018
Corportate registration number 548-86-00995

{"google":[],"custom":["Noto Sans KR"]}